Scott Lewis, MBA

Scott Lewis is Head of Strategic Planning at Rectify. Scott is a strategic biotech leader with over 15 years of experience. Prior to joining Rectify, Scott served as Vice President of Corporate Development and Strategy at Anjarium Biosciences, where he helped lead a strategic pivot from gene therapy drug discovery to the commercialization of a synthetic DNA manufacturing platform, later resulting in the company’s acquisition by a global CDMO.

Previously, Scott held roles of increasing responsibility at Cerevel Therapeutics, Biogen, and AstraZeneca, focused on early commercial strategy, portfolio management, program leadership and business development, with contributions to six commercialized therapies. Earlier, Scott was a bench scientist at Archemix Corporation, developing novel assays for oligonucleotide-based therapies. Scott earned a B.S. in Microbiology from Michigan State University and an M.B.A. from the University of Maryland, Robert H. Smith School of Business.